Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

doi:10.4251/wjgo.v13.i8.772

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6318)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

383

WORD

149

HTML

3220

Tables (1-5)

351

Sum=4103

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

312

Download

697

Sum=1009

Publishing Process of This Article

Item

Count

Browse

524

Download

682

Sum=1206

Aug 15, 2021 (publication date) through Aug 24, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Aug 15, 2021; 13(8): 772-798
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772

Table 5 Selected retrospective studies reporting prevalence of gastrointestinal immune-related adverse events in inflammatory bowel disease patients treated with all immune checkpoint inhibitor regimens

Ref.	Number of IBD patients	Single or multi center	Prevalence of GI irAE (%)
Abu-Sbeih et al[112], 2020	102	Multi	41.2
Grover et al[113], 2020	21	Single	28.0
Braga Neto et al[114], 2021	13	Single	30.7
Meserve et al[115], 2021	193 across 12 studies	Meta-analysis	40.0

IBD: Inflammatory bowel disease; GI: Gastrointestinal; irAE: Immune-related adverse events.

Citation: Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798
URL: https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.772